SCHEMBL4192341

SCHEMBL4192341

CCOC(=O)/C=C/c1ccc(CN2CCN(C(=O)O)[C@@H](C)C2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.41
ENPP2 Q13822 5/20 0.40
CCR1 P32246 7/20 0.40
MGLL Q99685 2/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4192349 1.00 KMT2A (0.41) KMT2AENPP2CCR1MGLLPTGDR2
SCHEMBL1704163 0.88 PDK1 (0.44) MGLLHDAC3HDAC1HDAC2HDAC8
SCHEMBL1704653 0.78 PDK1 (0.46) MGLLPTGDR2HDAC3HDAC1HDAC2
SCHEMBL1704651 0.78 PDK1 (0.46) MGLLPTGDR2HDAC3HDAC1HDAC2
SCHEMBL20483640 0.77 MGLL (0.46) KMT2ACCR1MGLLPTGDR2FPR3
SCHEMBL20483641 0.77 MGLL (0.46) KMT2ACCR1MGLLPTGDR2FPR3
SCHEMBL2767158 0.75 MGLL (0.44) KMT2ACCR1MGLLPTGDR2FPR3
SCHEMBL1704166 0.74 KDM4E (0.40) KMT2AKDM4EALDH1A1HDAC3HDAC4
SCHEMBL28653667 0.73 MGLL (0.51) CCR1MGLLPTGDR2FPR3GPR65
SCHEMBL28927825 0.73 MGLL (0.51) CCR1MGLLPTGDR2FPR3GPR65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130317041-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-11-28 US disclosed
US-8536182-B2 Benzylpiperazine derivatives and their medical use GLAXO GROUP LIMITED (GB) 2013-09-17 US disclosed
EP-1907374-B1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders GLAXO GROUP LTD (GB) 2012-08-22 EP disclosed
US-20090054456-A1 BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE GLAXO GROUP LIMITED (GB) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054456-A1 BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE GPR68, GPR88, GPR55 KMT2A 3278/4885ENPP2 279/4885CCR1 1073/4885
US-20130317041-A1 COMPOUNDS GPR68, GPR88, GPR35 KMT2A 3208/4885ENPP2 339/4885CCR1 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.